The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.565
Low: 1.475
Prev. Close: 1.65
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests

Fri, 01st May 2020 13:28

(Alliance News) - The following is a round-up of updates by London-listed companies on the impact of the Covid-19 pandemic, issued on Friday and not separately reported by Alliance News:

----------

Avacta Group PLC - biotherapeutics - Partnering with US-based Adeptrix to develop Covid-19 antigen test.

----------

Genedrive PLC - molecular diagnostics - Says development of SARS-CoV-2 testing kit passes manufacturing milestone. On track for CE marking in roughly three weeks.

----------

Inspiration Healthcare Group PLC - medical equipment - Says first consignment of ventilators arrived from supplier to the UK to be used by NHS.

----------

Frontier IP Group PLC - investor - Molendotech investee secures GBP425,000 in equity raise to fund development of rapid testing product for harmful bacteria. Says product receiving interest from potential customers attempting to tackle Covid-19.

----------

Catenae Innovation PLC - digital media - Builds data-protection compliant platform named Cov-ID to track user's Covid-19 test status. Expects project to enter trialling and finalisation phase in mid-May.

----------

Shield Therapeutics PLC - pharmaceuticals - Says manufacturing partners for Feraccru iron deficiency product continuing to work undisrupted. Too early to say whether sales in Germany and UK will hurt by Covid-19.

----------

Metals Exploration PLC - exploration and development - Operations in Philippines reduced to minimum to obey government measures. Says supply chain interruptions have meant some equipment deliveries delayed.

----------

Angus Energy PLC - oil and gas development - Says work to restart gas production at Saltfleetby continuing on schedule. In April sent tenders to bidders for various items for gas production at site. Says delaying bidding deadline due to Covid-19.

----------

Rose Petroleum PLC - oil and gas - Taken action to cost cuts amid virus and failed OPEC talks causing crude market turmoil. Directors taking 50% salary cut. Seeking shareholder approval for name change to Zephyr Energy PLC following restructuring last year.

----------

Rainbow Rare Earths Ltd - rare earth element miner - Says Gakara operations in Burundi continued mostly unhampered by Covid-19. Says 100 tonnes of concentrate reached Dar es Salaam, Tanzania by road due to air travel restrictions. Work continuing for maiden JORC resource.

----------

Igas Energy PLC - hydrocarbon producer - Shutting down some operations in May and June due to low oil price and market volatility. Closure to reduce production by about 600 barrels of oil equivalent per day. Will save roughly GBP500,000 in costs over the two months.

----------

Petra Diamonds Ltd - diamond miner - Says South African operations scaled up to 50% capacity as lockdowns ease. Says 3.8 million carats production guidance remains suspended. Chief executive and finance director take 25% salary cut.

----------

Ferro-Alloy Resources Ltd - vanadium mining - Says full-year results delayed amid UK Financial Conduct Authority moratorium. Production of acid-recoverable concentrates temporarily suspended due to Covid-19; other operations continue but at slower pace.

----------

Thor Mining PLC - tungsten explorer - Reducing costs and taking advantage of Covid-19 financial aid by Australian government.

----------

Lekoil Ltd - oil producer - Defers final USD7.6 million tranche of payment to Optimum Petroleum Development Co to cover costs at OPL 310 License. Payment now split into three tranches, starting with USD1.0 million in July before USD2.0 million in September.

----------

Danakali Ltd - potash producer - Says on-site activities in Eritrea suspended due to Covid-19. Expecting reduced costs in second quarter due to savings.

----------

Prairie Mining Ltd - coal developer - Poland operations limited as a result of pandemic travel restrictions.

----------

Bisichi PLC - miner - Says 2019 results delayed beyond April 30, after UK financial regulator allowed an extra two months.

----------

Salt Lake Potash Ltd - potash producer - Says virus has not had material impact on project schedules; operational changes in place to minimise Covid-19 impact. Directors and executives take 40% pay cut to save costs.

----------

Riverstone Credit Opportunities Income PLC - investor - Fair value of portfolio down 4.1% on March 31 from December 31 due to Covid-19 market turmoil and volatile commodity prices.

----------

Princess Private Equity Holding Ltd - investor - Says March 31 net asset value returns negative 14.1% in March alone and negative 14.8% in first quarter amid Covid-19 impact on markets.

----------

Arden Partners PLC - stockbroker - Says start to six months to April 30 was strong, despite UK political uncertainty amid Brexit and general election. Equity trading operation suffered "material losses" amid market response to virus. Says annual costs to be 25% lower year-on-year and board taking 40% salary cut. Some staff furloughed.

----------

James Cropper PLC - paper and advanced materials - Adjusted pretax profit for year ended March 28 to be in excess of GBP6 million, ahead of market expectations. Reports virus has reduced product demand across all divisions.

----------

Brickability Group PLC - construction materials - To begin re-opening of sites from Friday onwards.

----------

Quadrise Fuels International PLC - heavy fuel oil alternatives maker - Says GBP500,000 of cost savings achieved, meaning it can operate until second quarter of 2021 based on existing funds. Says operations continuing to "very good effect" despite Covid-19 restrictions.

----------

HML Holdings PLC - property services - Says profits for year ended March 31 slightly behind management expectations. Does not anticipate long-term impact from Covid-19, but sees reduction in ancillary revenue streams in the short-term.

----------

SpaceandPeople PLC - retail space selling and marketing - Reports GBP1 million funding application under UK's coronavirus business interruption loan scheme is successful.

----------

Bonhill Group PLC - media firm - Biggest impact from pandemic has been on events business. Says most events moved to second quarter. Furloughs 10% of UK workforce, reduces hours and implementes hiring freeze. Says cost cuts have led to savings of GBP2.5 million.

----------

Frontier Developments PLC - video game developer - Says lockdowns boosting demand and video game sales rising. Expects revenue for year to May 31 at top end of GBP65 million and GBP73 million range.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more
3 Apr 2019 10:10

Shield Therapeutics narrows losses as it advances Feraccru to market

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.

Read more
3 Apr 2019 09:56

Shield Therapeutics Cuts Loss In 2018; Licence Payment Lifts Revenue

LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a

Read more
14 Mar 2019 15:52

Shield Therapeutics Secures Positive Decision On Feraccru's Patent

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru

Read more
4 Mar 2019 11:26

Shield Therapeutics upbeat on latest Feraccru trial results

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.

Read more
29 Jan 2019 11:21

Shield Therapeutics Gets Positive Results From Feraccru Study

LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a

Read more
29 Jan 2019 10:02

Shield Therapeutics upbeat on results of latest Feraccru study

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.

Read more
24 Jan 2019 14:16

Shield Therapeutics Expects 2018 Revenue Growth On Licence Payments

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in

Read more
24 Jan 2019 10:02

Shield Therapeutics revenues surge following commercialisation deal

(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.

Read more
22 Jan 2019 13:35

Shield Therapeutics Appoints Director James Karis As Chair

LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's

Read more
22 Jan 2019 09:56

Shield Therapeutics promotes Karis to chairman

(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.

Read more
13 Dec 2018 11:57

FDA gives target date for Shield's Feraccru application

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.

Read more
5 Dec 2018 13:07

Shield Therapeutics' Feraccru treatment launched in UK

(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.

Read more
5 Dec 2018 11:57

Shield Therapeutics Partner Norgine Launches Feraccru In UK

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield,

Read more
24 Sep 2018 14:30

DIRECTOR DEALINGS: Shield Therapeutics Boss Sterritt Buys More Stock

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.